Learning Objectives Evaluate the mechanism of action of vandetanib in the care of patients
with thyroid cancer. Analyze the current status of clinical development and early clinical …

Pancreatic cancer is a deadly malignancy with still high mortality and poor survival despite
the significant advances in understanding, diagnosis, and access to conventional and novel …

Background Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The high
risk of recurrence following surgical resection provides the rationale for adjuvant therapy …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal form of cancer characterized by
drug resistance, urging new therapeutic strategies. In recent years, protein kinases have …

A new series of nortopsentin analogs, in which the central imidazole ring of the natural lead
was replaced by a 1, 3, 4-oxadiazole or 1, 3, 4-thiadiazole moiety, was efficiently …

Because the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited set of
known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics …

Vandetanib did not demonstrate any superiority alone or in combination with gemcitabine in
the progression-free survival of patients affected by advanced biliary tract cancer compared …

Background Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but
only marginally improved median overall survival when combined with gemcitabine in …

Drugs that target human thymidylate synthase (hTS), a dimeric enzyme, are widely used in
anticancer therapy. However, treatment with classical substrate-site-directed TS inhibitors …